Kruppel-like factor 9 (KLF9)

Kruppel-like factor 9 (KLF9), also known as Basic transcription element-binding protein 1 (BTEB1), is a zinc-finger transcription factor that plays a pivotal role in regulating gene expression by binding to GC-rich promoter sequences [UniProt Q13886]. It is involved in a wide array of biological processes, including cell differentiation, proliferation, and the response to oxidative stress [PubMed: 25611386]. In oncology, KLF9 typically functions as a tumor suppressor; its downregulation is frequently observed in cancers such as breast, colorectal, and endometrial carcinoma, where it normally acts to inhibit cell growth and promote apoptosis [PubMed: 28423570]. Beyond cancer, KLF9 is a key mediator of hormonal signaling, particularly for glucocorticoids and thyroid hormones, influencing metabolic pathways and neuronal maturation [PubMed: 23396110]. While there are currently no FDA-approved drugs that directly target KLF9, it is considered a significant therapeutic target for its ability to modulate ferroptosis and oxidative stress pathways in resistant tumors [PubMed: 33064111]. Therapeutic strategies often focus on restoring its expression or leveraging its downstream effects to sensitize cells to existing treatments. Its role in hepatic gluconeogenesis also makes it a potential target for metabolic disorders like type 2 diabetes [PubMed: 23396110]. Furthermore, KLF9 is essential for proper brain development, specifically in the regulation of oligodendrocyte differentiation and myelin formation [PubMed: 15659595].

Other names

Basic transcription element-binding protein 1BTEB1BTEBGC-box-binding proteinKrueppel-like factor 9

Transcription factor modulation; binds to GC-rich promoter elements to regulate gene expression involved in cell cycle arrest, apoptosis, and metabolic homeostasis.